Chat With UsChat With UsBy Mir Moomin • 16 October 2026
Ultragenyx Pharmaceutical has agreed to sell two FDA Priority Review Vouchers for a combined $413 million, creating a significant source of funding as the biotechnology company advances its rare-disease treatment portfolio.
Ultragenyx Pharmaceutical has announced two agreements to sell US Food and Drug Administration (FDA) Priority Review Vouchers (PRVs), generating a combined transaction value of $413 million. The agreements follow the FDA approvals of two gene therapies developed for rare genetic diseases.
The first agreement, announced on October 7, 2026, valued a voucher at $210 million. A second agreement, announced on October 14, 2026, valued another voucher at $203 million. The buyers were not publicly disclosed in the reported announcements.
The vouchers were awarded following FDA approvals of Genglycos, developed for glycogen storage disease type Ia, and Fayuvi, developed for Sanfilippo syndrome type A.
Both conditions are rare genetic disorders that can have significant effects on patients and their families. Gene therapies aim to address underlying disease mechanisms by introducing genetic material or enabling a functional genetic intervention, potentially offering benefits beyond conventional symptom management.
The approvals enabled Ultragenyx to access an additional financial opportunity through the regulatory voucher programme.
FDA Priority Review Vouchers provide eligible holders with the opportunity to request priority review for a future qualifying drug application. Priority review generally targets an FDA decision within six months, compared with the standard review goal of ten months for applicable drug applications.
These vouchers can be transferred or sold, creating a secondary market in which pharmaceutical companies may pay substantial sums to accelerate regulatory review of another product.
For Ultragenyx, selling the vouchers offers a way to generate capital without issuing additional shares. The proceeds could support research and development, commercial operations and other corporate priorities.
The $413 million in announced voucher-sale agreements comes at an important time for the company as it navigates the costs and uncertainties associated with developing treatments for rare diseases.
Drug development requires significant investment in research, clinical trials, regulatory submissions and commercial preparation. Additional capital from voucher sales could provide greater flexibility as Ultragenyx works to advance its pipeline and bring approved therapies to patients.
However, the transaction value should not be confused with recurring product revenue. The voucher sales represent one-time proceeds, and the agreements remain subject to their applicable closing conditions.
The transactions highlight how regulatory incentives can create financial value beyond the direct commercial sales of medicines. For biotechnology companies working in rare-disease areas, such programmes can provide an additional potential source of funding alongside licensing agreements, partnerships and product revenue.
The long-term impact will depend on Ultragenyx's ability to translate its regulatory approvals into patient access, commercial adoption and sustainable revenue.
The combined $413 million in voucher-sale agreements represents a substantial potential financial benefit for the company, while underscoring the role of regulatory incentives in supporting innovation in rare-disease drug development.